Matrix Metalloproteinases in Multiple Myeloma

References

• Chambers A. F., Matrisian L. M. Review: Changing views of the role of matrix metalloprotienases in metastasis. J. Natl. Cancer Inst. 1997; 89: 1260–1270
   PubMed Web of Science ®Google Scholar
• Werb Z. ECM and cell surface proteolysis: regulating cellular ecology. [Review] [20 refs]. Cell 1997; 91(4)439–42
   PubMed Web of Science ®Google Scholar
• Fingleton B. M., Goss K. J., Heppner Crawford H. C., Matrisian L. M. Matrilysin in early stage intestinal tumorigenesis. APMIS 1999; 107: 102–110
   PubMed Web of Science ®Google Scholar
• Sato T., Foged N. T., Delaisse J. M. The migration of purified osteoclasts through collagen is inhibited by matrix metalloproteinase inhibitors. Journal of Bone & Mineral Research 1998; 13(1)59–66
   PubMed Web of Science ®Google Scholar
• Blavier L., Delaisse J. M. Matrix metalloproteinases are obligatory for the migration of preosteoclasts to the developing marrow cavity of primitive long bones. J. Cell Sci. 1995; 108(Pt 12)3649–59
   PubMedGoogle Scholar
• Everts V., Delaisse J. M., Korper W., Beertsen W. Cysteine proteinases and matrix metalloproteinases play distinct roles in the subosteoclastic resorption zone. J. Bone & Min. Res. 1998; 13(9)1420–30
   PubMed Web of Science ®Google Scholar
• Holliday L. S., Welgus H. G., Fliszar C. J., Veith G. M., Jeffrey J. J., Gluck S. L. Initiation of osteoclast bone resorption by interstitial collagenase. J. Biol. Chem. 1997; 272(35)22053–8
   PubMed Web of Science ®Google Scholar
• Hill P. A. G., Murphy A. J., Docherty R. M., Hembry T. A., Millican Reynolds J. J., Meikle M. C. The effects of selective inhibitors of matrix metalloproteinases (MMPs) on bone resorption and the identification of MMPs and TIMP-1 in isolated osteoclasts. J. Cell Sci. 1994; 107(Pt 11)3055–64
   PubMed Web of Science ®Google Scholar
• Witty J. P., Foster S. A., Stricklin G. P., Matrisian L. M., Stern P. H. Parathyroid hormone-induced resorption in fetal rat limb bones is associated with production of the metalloproteinases collagenase and gelatinase B. J. Bone & Min. Res. 1996; 11(1)72–8
   PubMed Web of Science ®Google Scholar
• Kusano K., Miyaura C., Inada M., Tamura T., Ito A., Nagase H., Kamoi K., Suda T. Regulation of matrix metalloproteinases (MMP-2, -3, -9, and -13) by interleukin-1 and interleukin-6 in mouse calvaria: association of MMP induction with bone resorption. Endocrinology 1998; 139(3)1338–45
   PubMed Web of Science ®Google Scholar
• Tezuka K., Nemoto K., Tezuka Y., Sato T., Ikeda Y., Kobori M., Eguchi H., Hakeda Y., Kumegawa M. Identification of matrix metalloprotienase-9 in rabbit osteoclasts. J. Biol. Chem. 1994; 269: 15006–15009
   PubMed Web of Science ®Google Scholar
• Aimes R. T., Quigley J. P. Matrix metalloproteinase-2 is an interstitial collagenase. J. Biol. Chem. 1995; 270: 5872–5876
   PubMed Web of Science ®Google Scholar
• Williams S., Barnes J., Wakisaka A., Ogasa H., Liang C. T. Treatment of osteoporosis with MMP inhibitors. Ann. NY Acad. Sci. 1999; 878: 191–200
   PubMed Web of Science ®Google Scholar
• Teronen O. P., Heikkila Konttinen Y. T., Laitinen M., Salo T., Hanemaaijer R., Teronen A., Maisi P., Sorsa T. MMP inhibition and downregulation by bisphosphonates. Ann. NY Acad. Sci. 1999; 878: 453–65
   PubMed Web of Science ®Google Scholar
• Bataille R., Harousseau J. L. Multiple myeloma. [Review] [100 refs]. New Eng. J. Med. 1997; 336(23)1657–64
   PubMed Web of Science ®Google Scholar
• Bataille R., Manolagas S. C., Berenson J. R. Pathogenesis and management of bone lesions in multiple myeloma. [Review] [80 refs]. Hematology - Oncology Clinics of North America 1997; 11(2)349–61
   PubMed Web of Science ®Google Scholar
• Borset M., Helseth E., Naume B., Waage A. Lack of IL-1 secretion from human myeloma cells highly purified by immunomagnetic separation. Brit. J. Haem. 1993; 85: 446–451
   PubMed Web of Science ®Google Scholar
• Barille S., Akhoundi C. M., Coliette M. P., Mellerin M. J., Rapp Harousseau J. L., Bataille R., Amiot M. Metalloproteinases in multiple myeloma: production of matrix met-alloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells. Blood 1997; 90(4)1649–55
   PubMed Web of Science ®Google Scholar
• Kaushal G. P., Xiong X., Athota A. B., Rozypal T. L., Sanderson R. D., Kelly T. Syndecan-1 expression suppresses the level of myeloma matrix metalloproteinase-9. Brit. J. Haem. 1999; 104: 365–373
   PubMed Web of Science ®Google Scholar
• Vacca A., Ribatti D., Presta M., Minischetti M., Lurlaro M., Ria R., Albini A., Bussolino F., Dammacco F. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 1999; 93(9)3064–73
   PubMed Web of Science ®Google Scholar
• Yoneda T, Sasaki A. C., Dunstan P. J., Williams F., DeClerck Bauss Y. A., Mundy G. R. Inhbition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of matrix metalloproteinase-2. J. Clin. Invest. 1997; 99: 2501–2517
   Web of Science ®Google Scholar
• Bataille R. New insights in the clinical biology of multiple myeloma. [Review] [48 refs]. Seminars in Hematology 1997; 34(1)23–8, Suppl 1
   PubMed Web of Science ®Google Scholar
• Koop S. R., Khokha E. E., Schmidt I. C., MacDonald V. L., Morris Chambers A. F., Groom A. C. Overexpression of metalloproteinase inhibitor in B16F10 cells does not affect extravasation but reduces tumor growth. Cancer Res. 1994; 54: 4791–4797
   PubMed Web of Science ®Google Scholar
• Kim J., Yu W., Kovalski K., Ossowski L. Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay. Cell 1998; 94(3)353–62
   PubMed Web of Science ®Google Scholar
• Quigley J. P., Armstrong P. B. Tumor cell intravasation Alu-cidated: The chick embryo opens the window. Cell 1998; 94: 281–284
   PubMed Web of Science ®Google Scholar
• Ribatti D., Vacca A., Nico B., Quondamatteo F., Ria R., Minischetti M., Marzullo A., Herken R., Roncali L., Dammacco F. Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma. Brit. J. Cancer 1999; 79(3–4)451–5
   PubMed Web of Science ®Google Scholar
• Vacca A., Ribatti D., Roncali L., Ranieri G., Serio G., Sil-Vestris F., Dammacco F. Bone marrow angiogenesis and progression in multiple myeloma. Brit. J. Haem. 1994; 87(3)503–8
   PubMed Web of Science ®Google Scholar
• Vacca A., Ribatti D., Roncali L., Dammacco F. Angiogenesis in B cell lymphoproliferative diseases. Biological and clinical studies. [Review] [61 refs]. Leukemia & Lymphoma 1995; 20(1–2)27–38
   PubMed Web of Science ®Google Scholar
• Vacca A., Ribatti D., Lurlaro M., Albini A., Minischetti M., Bussolino F., Pellegrino A., Ria R., Rusnati M., Presta M. V., Vincenti Persico M. G., Dammacco F. Human lymphoblastoid cells produce extracellular matrix-degrading enzymes and induce endothelial cell proliferation, migration, morphogenesis, and angiogenesis. Intl J. Clin. Lab. Res. 1998; 28(1)55–68
   PubMedGoogle Scholar
• Henriet P., Blavier L., Declerck Y. A. Tissue inhibitors of metalloproteinases (TIMP) in invasion and proliferation. APMIS 1999; 107: 111–119
   PubMed Web of Science ®Google Scholar
• Wilson C., Heppner K. J., Plabosky A., Hogan B. L.M., Matrisian L. M. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc. Natl. Acad. Sci. USA 1997; 94: 1402–1407
   PubMed Web of Science ®Google Scholar
• Carey D. J. Syndecans: multifunctional cell-surface co-receptors. [Review] [155 refs]. Biochem. J. 1997; 327(Pt 1)1–16
   PubMedGoogle Scholar
• Ridley R. C., Xiao H., Hata H., Woodliff J., Epstein J., Sanderson R. D. Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen. Blood 1993; 81(3)767–74
   PubMed Web of Science ®Google Scholar
• Liebersbach B. F., Sanderson R. D. Expression of syndecan-1 inhibits cell invasion into type I collagen. J. Biol. Chem. 1994; 269(31)20013–20019
   PubMed Web of Science ®Google Scholar
• Stanley M. J., Liebersbach B. F., Liu W., Anhalt D. J., Sanderson R. D. Heparan sulfate-mediated cell aggregation. Syndecans-1 and -4 mediate intercellular adhesion following their transfection into human B lymphoid cells. J. Biol. Chem. 1995; 270(10)5077–83
   PubMed Web of Science ®Google Scholar
• Dhodapkar M. V., Abe E., Theus A. M., Lacy Langford J. K., Barlogie B., Sanderson R. D. Syndecan-1 is a multifunctional regulator of myeloma pathobiology: Control of tumor cell survival, growth, and bone cell differentiation. Blood 1998; 91: 2679–2688
   PubMed Web of Science ®Google Scholar
• Dhodapkar M. V., Kelly T. A., Theus Athota A. B., Barlogie B., Sanderson R. D. Elevated levels of shed syndecan-1 correlate with tumour mass and decreased matrix metallopro-teinase-9 activity in the serum of patients with multiple myeloma. Brit. J. Haem. 1997; 99: 368–371
   PubMed Web of Science ®Google Scholar